1. A Case of Pancreatic Neuroendocrine Tumor G3 Which Responded Remarkably to Chemotherapy
- Author
-
Satoru NEBUYA, Shinji OE, Yoshikazu HARADA, Yusuke TAKEUCHI, Akitoshi YONEDA, Yudai KOYA, Koichiro MIYAGAWA, Yuichi HONMA, Michihiko SHIBATA, and Masaru HARADA
- Subjects
Pancreatic Neoplasms ,Neuroendocrine Tumors ,Public Health, Environmental and Occupational Health ,Humans ,Female ,General Medicine ,Neoplasm Grading ,Streptozocin - Abstract
Pancreatic neuroendocrine carcinoma (NEC) as classified in the World Health Organization (WHO) 2010 was reclassified in the WHO 2017 as either neuroendocrine tumor (NET) G3 or NEC. An accurate diagnosis based on the WHO 2017 classification is important in order treating this disease appropriately. We report a case diagnosed as NET G3 that responded remarkably well to treatment with streptozocin. The patient would likely not have received the streptozocin treatment if she had been diagnosed with NEC. The WHO 2017 classification is reasonable for the treatment of advanced pancreatic neuroendocrine neoplasms.
- Published
- 2022